ES2546154T3 - Ácidos indaniloxidihidrobenzofuranilacéticos, útiles para el tratamiento del síndrome metabólico - Google Patents

Ácidos indaniloxidihidrobenzofuranilacéticos, útiles para el tratamiento del síndrome metabólico Download PDF

Info

Publication number
ES2546154T3
ES2546154T3 ES11788845.3T ES11788845T ES2546154T3 ES 2546154 T3 ES2546154 T3 ES 2546154T3 ES 11788845 T ES11788845 T ES 11788845T ES 2546154 T3 ES2546154 T3 ES 2546154T3
Authority
ES
Spain
Prior art keywords
alkyl
groups
indan
group
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11788845.3T
Other languages
English (en)
Spanish (es)
Inventor
Frank Himmelsbach
Remko Bakker
Matthias Eckhardt
Dieter Hamprecht
Elke Langkopf
Holger Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2546154T3 publication Critical patent/ES2546154T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES11788845.3T 2010-12-01 2011-11-30 Ácidos indaniloxidihidrobenzofuranilacéticos, útiles para el tratamiento del síndrome metabólico Active ES2546154T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP10193382 2010-12-01
EP10193382 2010-12-01
EP11154999 2011-02-18
EP11154999 2011-02-18
EP11175646 2011-07-27
EP11175646 2011-07-27
PCT/EP2011/071410 WO2012072691A1 (en) 2010-12-01 2011-11-30 Indanyloxydihydrobenzofuranylacetic acids

Publications (1)

Publication Number Publication Date
ES2546154T3 true ES2546154T3 (es) 2015-09-21

Family

ID=45063142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11788845.3T Active ES2546154T3 (es) 2010-12-01 2011-11-30 Ácidos indaniloxidihidrobenzofuranilacéticos, útiles para el tratamiento del síndrome metabólico

Country Status (10)

Country Link
US (1) US20120302566A1 (enExample)
EP (1) EP2646425B1 (enExample)
JP (1) JP5853317B2 (enExample)
AR (1) AR084050A1 (enExample)
DK (1) DK2646425T3 (enExample)
ES (1) ES2546154T3 (enExample)
HU (1) HUE025363T2 (enExample)
PL (1) PL2646425T3 (enExample)
UY (1) UY33758A (enExample)
WO (1) WO2012072691A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8809376B2 (en) * 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2925748B1 (en) * 2012-11-28 2017-01-11 Boehringer Ingelheim International GmbH Indanyloxydihydrobenzofuranylacetic acids as modulators of the g-protein coupled receptor 40 (gpr40) and of the free fatty acid receptor 1 (ffar1) for the treatment of metabolic diseases
US20140163025A1 (en) * 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
JP6314335B2 (ja) * 2013-02-06 2018-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
CN105473595A (zh) * 2013-08-23 2016-04-06 福建海西新药创制有限公司 治疗糖尿病的羧酸化合物
EP3049396B1 (en) 2013-09-26 2017-11-15 Boehringer Ingelheim International GmbH Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
EP3068768B1 (en) 2013-11-15 2019-07-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3074375B1 (en) * 2013-11-28 2018-04-04 Boehringer Ingelheim International GmbH New indanyloxyphenylcyclopropanecarboxylic acids
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
CN104177320B (zh) * 2014-08-27 2016-03-02 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
WO2018138030A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110198928B (zh) 2017-01-26 2023-08-29 勃林格殷格翰国际有限公司 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
US10793530B2 (en) 2017-01-26 2020-10-06 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10919859B2 (en) 2017-01-26 2021-02-16 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7049353B2 (ja) * 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
US11225471B2 (en) 2017-11-16 2022-01-18 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
AR126196A1 (es) * 2021-06-23 2023-09-27 Blueprint Medicines Corp Proceso para preparar inhibidores de egfr
CN117384086A (zh) * 2023-10-08 2024-01-12 苏州凯瑞医药科技有限公司 一种手性2,2,2-三氟-1-(吡啶-2-基)乙烷-1-醇的合成方法
WO2025140655A1 (en) * 2023-12-30 2025-07-03 Fujian Haixi Pharmaceuticals Co., Ltd. Heteroaryl compounds as multi-target protein kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2628103B1 (fr) 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
WO2006065809A2 (en) 2004-12-16 2006-06-22 Exxonmobil Chemical Patents Inc. Heteroatom bridged metallocene compounds for olefin polymerization
EP1924546A1 (en) * 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
KR20080103584A (ko) * 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
WO2008054675A2 (en) * 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
KR20110027657A (ko) 2008-06-25 2011-03-16 다이이찌 산쿄 가부시키가이샤 카르복실산 화합물
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids

Also Published As

Publication number Publication date
UY33758A (es) 2012-06-29
PL2646425T3 (pl) 2015-12-31
HUE025363T2 (en) 2016-02-29
EP2646425B1 (en) 2015-06-10
AR084050A1 (es) 2013-04-17
JP2013544268A (ja) 2013-12-12
JP5853317B2 (ja) 2016-02-09
DK2646425T3 (en) 2015-08-24
US20120302566A1 (en) 2012-11-29
EP2646425A1 (en) 2013-10-09
WO2012072691A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
ES2546154T3 (es) Ácidos indaniloxidihidrobenzofuranilacéticos, útiles para el tratamiento del síndrome metabólico
EP2427444B1 (en) Inhibitors of the renal outer medullary potassium channel
CN108623615B (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
KR20100044197A (ko) 테트라하이드로피라노크로멘 감마 세크레타제 억제제
CN115380026A (zh) 蛋白降解调节剂与其使用方法
CN104918935B (zh) 二氢吡唑gpr40调节剂
CN113004269A (zh) Kras-G12C抑制剂杂环化合物
ES2765973T3 (es) Moduladores de GPR120 de ácido biciclo[2.2.2]
TW200800908A (en) Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
ES2635262T3 (es) Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
RS57170B1 (sr) Pirolidinski gpr40 modulatori za lečenje bolesti kao što je dijabetes
AU7562598A (en) Protease inhibitors
WO2015172732A1 (zh) 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
JP2017521399A (ja) 腎髄質外層カリウムチャンネルの阻害剤
JP2018502133A (ja) Ａｍｐ活性化タンパク質キナーゼのアゴニストとしての新規アザベンゾイミダゾール誘導体
KR20170021358A (ko) 신장 외수질성 칼륨 채널의 억제제
CN101223164A (zh) 作为肾素抑制剂的被取代的哌啶类
AU2015256038A1 (en) Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes
US6596715B1 (en) Protease inhibitors
WO2000029408A1 (en) Morpholino-ethoxybenzofuran protease inhibitors
US6534498B1 (en) Protease inhibitors
KR20230146607A (ko) Wee-1 억제제로서 피리미딘 화합물
EP4225735A1 (en) Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
ES2576082T3 (es) Derivado de paroxetina
WO2001034158A1 (en) Protease inhibitors